VivoSeq
Other

Oligometastases

0

Pipeline Programs↗

6

Active Trials↗

1

Companies Involved↗

Oligometastases is an early-stage landscape with 0 programs across 1 company. The most active players are Mario Negri Institute for Pharmacological Research.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

8

clinical trials

Recruiting4 · 50%
Active, not recruiting2 · 25%
Completed2 · 25%

Clinical Trials

Trial Activity

8 trials

SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases
Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT06850103·51 enrolled
A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.
Recruiting·—·Phase 3·NCT05717166·180 enrolled
BRAVE Study: QL1706 + Bevacizumab + SBRT for BCLC-C HCC With PVTT or Oligometastases
Recruiting·SShandong Cancer Hospital and Institute·Phase 2·NCT07062055·46 enrolled
Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen
Recruiting·Mario Negri Institute for Pharmacological Research logoMario Negri Institute for Pharmacological Research·Phase 2·NCT06680050·21 enrolled
Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC
Active, not recruiting·GGroupe Oncologie Radiotherapie Tete et Cou·Phase 2·NCT03070366·78 enrolled
Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients
Active, not recruiting·UUNICANCER·Phase 3·NCT04115007·550 enrolled
Stereotactic Body Radiation With Nelfinavir for Oligometastases
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT01728779·38 enrolled
SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs
Completed·FFudan University·Phase 2·NCT04764214·61 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)